Edwards Lifesciences Corp.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Edwards Lifesciences Corp.
Results from the TVT Registry suggest that TAVR may benefit patients who have severe aortic disease but few symptoms. Clinical trials specifically designed to answer that question are needed, according to an editorial in JACC
News We’re Watching: AHA Meeting In Philly; Surgeons Call For TAVR Caution; China Approves J&J's Monarch Robot
New clinical trial data presented at the American Heart Association Scientific Sessions in Philadelphia dominated the R&D news this week. Here are some of the highlights from the conference as well as some other bits of medtech industry news you may have missed.
News We're Watching: TCT Yields More Encouraging Results For TAVR; HeartPoint Resets Trial Plans, Butterfly Tries Brain-Interface Tech
Clinical trial results announced at the Transcatheter Therapeutics conference in San Francisco headlined the medtech research and development news last week. Noteworthy "commercial" developments in late October include iCad’s decision to sell its Xoft brachytherapy business to Elekta and Butterfly Network's plans to work with Forest Neurotech on brain-computer interfaces.
For medtechs, implementing an ESG strategy will need to become a priority as global rules are being introduced for companies to report ESG data. A panel discussion with medtech ESG leaders at the recent LSX Congress USA conference in Boston outlined some strategies and sustainability goals.
- Implantable Devices
- Infusion Therapy Equipment and Supplies
- Monitoring Equipment & Devices
- Surgical Equipment & Devices
- Other Names / Subsidiaries
- CardiAQ Valve Technologies, Inc.
- CAS Medical Systems, Inc.
- Embrella Cardiovascular, Inc.
- Harpoon Medical, Inc.
- Percutaneous Valve Technologies, Inc.
- Valtech Cardio, Ltd.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.